Absorption Systems named one of top 10 CROs in 2020

Exton, PA — June 03, 2020 — Absorption Systems, a renowned global provider of innovative pre-clinical analytical solutions to the pharmaceutical sector, has been recognized for its innovative cell and gene therapy testing services, being recently named among Pharma Tech Outlook’s Top 10 contract research organizations for 2020. The annual list highlights the leading organizations supporting pharmaceutical companies to effectively navigate the challenges of modern clinical development.

“The ever-growing recognition of Absorption Systems is a testament to our dedication to excellence, and our success in enabling customers to overcome the complex barriers faced when developing novel drugs and medical devices,” said Patrick Dentinger, Chief Executive Officer of Absorption Systems. “Through our innovative research tools, exceptionally trained scientific experts and rich history of pre-clinical expertise, we’ll continue to streamline approval processes and help companies to more comprehensively predict drug outcomes in humans.”

For more than 20 years, Absorption Systems has supported its extensive client base through analytics-enabled test systems, streamlined protocols and custom model development across its three US-based facilities. In 2017, Absorption Systems leveraged this experience to launch a specialized cell and gene therapy division, offering a wide spectrum of first-in-class in vitro and in vivo testing services, specializing in testing a product’s potency outside of humans.

“Bringing cell and gene therapy products to market is a convoluted process, with complex mechanisms of action and changing manufacturing processes making development of validated potency assays particularly difficult,” commented Dentinger. “But, being able to draw on decades of successful partnerships, and with facilities and systems that exceed regulatory standards, Absorption Systems is ideally placed to support cell and gene therapy developers through assay development and the GMP process.”

In addition to its cell and gene therapy services, Absorption Systems continues to support the wider drug development industry in the current COVID-19 pandemic with a range of capabilities that can be used to advance COVID-19 testing and vaccine development. For non-COVID-19 products, Absorption Systems offers ways to progress these towards approval using in vitro data to reduce the need for human studies.

For more information about  the cell and gene therapy and COVID-19 support services offered by Absorption Systems, please visit: https://www.absorption.com/

To read a recent article about the cell and gene therapy services of Absorption Systems, please visit: https://www.absorption.com/absorption-systems-accelerating-product-lifecycle-from-concept-to-approval/ 

About Absorption Systems

Absorption Systems, founded in 1996, assists pharmaceutical, biotechnology and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs, biologics and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. From early stage research through commercial and post market surveillance, Absorption Systems is committed to providing the most physiologically relevant test systems with highest quality. For information on the company's comprehensive contract services, applied research programs, and proprietary test systems, please visit www.absorption.com.

Contact

For more information:

Jaleel Shujath

Jshujath@absorption.com

Media enquires:
Helen Stewart-Miller

BioStrata

+44 1223 627120

hstewartmiller@biostratamarketing.com